Outcomes of a remote, decentralized health center-based HIV/AIDS antiretroviral program in Zambia, 2003 to 2007

Journal of the International Association of Physicians in AIDS Care

Volumn 8, Issue 1, 2009, Pages 60-67

  Elema, Riekje ^a   Mills, Clair ^a   Yun, Oliver ^a   Lokuge, Kamalini ^c   Ssonko, Charles ^a   Nyirongo, Nashiola ^a   Mtonga, Velepi ^b   Zulu, Henry ^b   Tu, David ^a   Verputten, Meggy ^c   O'Brien, Daniel P ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b MINISTRY OF HEALTH   (Zambia)

^c Ministry of Health ^*

Author keywords

antiretroviral therapy; HIV; rural health centers; sub Saharan Africa; viral load

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RISK FACTOR; RURAL HEALTH CARE; STATISTICAL MODEL; TREATMENT OUTCOME; VIRUS LOAD; ZAMBIA;

ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HUMANS; LAMIVUDINE; LOGISTIC MODELS; MALE; MIDDLE AGED; NEVIRAPINE; PATIENT COMPLIANCE; RISK FACTORS; RURAL HEALTH SERVICES; STAVUDINE; TREATMENT OUTCOME; VIRAL LOAD; ZAMBIA;

EID: 67649337201     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109709331472     Document Type: Article

References (17)

1. Unaids / WHO Epidemiological Fact Sheets on HIV and AIDS, 2008 Update. Zambia. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance ; July 2008; Geneva, Switzerland.
2. Akileswaran C., Lurie MN, Flanigan TP, Mayer KH Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis. 2005 ; 41: 376-385. (Pubitemid 41022117)
3. Bedelu M., Ford N., Hilderbrand K., Reuter H. Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis. 2007 ; 196 (suppl 3). S464 - S468.
4. Ferradini L., Jeannin A., Pinoges L., et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006 ; 367: 1335-1342.
5. Calmy A., Pinoges L., Cirera A., et al. Increased access to ART in resource-poor settings in Medecins Sans Frontières programmes: outcomes of adults at 18 months of treatment. Presented at: XV International AIDS Conference ; 2004 ; Bangkok, Thailand. [abstract THPEB7179].
6. Ahoua L., Guenther G., Olaro C., et al. Evaluation of antiretroviral therapy for HIV+ adults and children in the Arua HIV/AIDS care program, Uganda, January 2007. Final report, Epicentre and MSF.
7. Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006 ; 367: 817-824.
8. Ivers LC, Kendrick D., Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis. 2005 ; 41: 217-224. (Pubitemid 40962502)
9. Etard J., Ndiaye I., Thierry-Mieg M., et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort. AIDS. 2006 ; 20: 1181-1189. (Pubitemid 43786107)
10. Zachariah R., Fitzgerald M., Massaquoi M., et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS. 2006 ; 20: 2355-2360. (Pubitemid 44789538)
11. Bates I., Fenton C., Gruber J., et al. Vulnerability to malaria, tuberculosis, and HIV/AIDS infection and disease. Part 1: determinants operating at individual and household level. Lancet Infect Dis. 2004 ; 4: 267-277.
12. Grabar S., Kousignian I., Sobel A., et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS. 2004 ; 18: 2029-2038. (Pubitemid 39463356)
13. Alcorn K. First-line treatment choices proving challenging for African ART programmes. Aidsmap. June 27, 2007.
14. Pujades-Rodríguez M., O'Brien D., Humblet P., Calmy A. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières. AIDS. 2008 ; 22: 1305-1312.
15. Murri R., Lepri AC, Cicconi P., et al, ICoNA Study Group. Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naive patients study. J Acquir Immune Defic Syndr. 2006 ; 41: 23-30. (Pubitemid 41786015)
16. Chaiwarith R., Wachirakaphan C., Kotarathititum W., Praparatanaphan J., Sirisanthana T., Supparatpinyo K. Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand. Int J Infect Dis. 2007 ; 11: 413-416. (Pubitemid 47239450)
17. Sungkanuparph S., Manosuthi W., Kiertiburanakul S., Chantratital W. Reply to Vogenthaler. Clin Infect Dis. 2007 ; 44: 1387-1388 [letter].